Skip to main
SMTI

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech Inc. has demonstrated strong sales growth in its surgical soft tissue repair products, with a 24% year-over-year increase, resulting in revenues of $23.4 million, signaling heightened demand for its key offerings such as CellerateRX Surgical and BIASURGE. The company’s preliminary financial results indicate a positive trajectory, with expected revenue growth of 13-17% for 2026 and profitability achieved in the third quarter of 2025. Furthermore, strategic partnerships, including a new contract with Vizient that enhances market access and operational efficiency, position Sanara MedTech favorably for sustainable revenue growth and improved profitability in the future.

Bears say

Sanara MedTech reported net revenue of $26.3 million, reflecting a year-over-year growth of 21.5%, which was slightly below expectations. The company faces several risks that could adversely impact future performance, including lower-than-projected revenue growth, challenges in acquiring new customers, delays in product launches, and the potential for shareholder dilution. Additionally, a revision of the company's EV/Revenue multiple from 4.3x to 3.0x indicates a diminished outlook following the exclusion of telehealth from its business model.

SMTI has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.